The new mechanism identified here provides a rationale for the therapeutic use of SMYD3 inhibitors to mitigate the efficacy of alkylation chemotherapy in first- or second-line treatments for patients with SCLC. The gene discussed is SMYD3; the disease is small cell lung carcinoma.